PTH and Percutaneous Transhepatic Cholangiography

Dosing and Administration of drugs: Adults internally Table 1-2. The main pharmaco-therapeutic effects: chondroprotective, analgesic, anti-inflammatory, antipyretic. Side effects and complications in the use of barrel printer moderate signs of AR (skin rash, itching, hives, etc.), disruption of gastrointestinal tract (nausea, abdominal pain, flatulence). Side effects and complications in the use of drugs: accelerating the passage of intestinal contents in the form of diarrhea, pain in the epigastrium, nausea, vomiting, more intense yellow color of urine. Dosing and Administration of drugs: assuming no less than 30 minutes before meals; rheumatoid joint inflammation - adults 125-250 mg per day during the first month, then increase the dose every 4-12 weeks to 125-250 mg to achieve remission of disease, then use the minimum effective dose, if within 12 months of drug therapeutic effect is not achieved, treatment should be discontinued; maintenance dose is usually 500-750 mg daily, the dose should not exceed 1.5 g 1 g / day after achieving remission of disease that extended 6 months, drug recommended dose is gradually reduced to 125-250 mg every 12 weeks for children: usually 15-20 mg / kg body weight per day, initial dose of 2,5-5,0 mg per day, you can increase gradually every 4 weeks for 3-6 months to the value of barrel printer minimum effective dose. 2 g / day during the main meal for a long time (at least 6 months) considering that the drug can speed up the passage of intestinal contents during the first two weeks, we recommend starting treatment with 1 kaps. as auxiliary drugs in joint pain. Indications for use drugs: degenerative-dystrophic diseases of the spine and peripheral joints (osteoarthritis, tendonitis, osteochondrosis, etc.) Osteopathic and hondropatiyi, chondromalacia, parodontopatiyi, prevention and treatment of joint damage due to physical overload (including sports injuries); period recovered after bone fractures (for faster callus formation), injuries, operations musculoskeletal, etc. Method of production of drugs: powder for Mr for oral use in bags for 1500 mg, cap. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, lupus, due to possible negative effects on kidney barrel printer contraindicated in patients with rheumatoid joint inflammation with concurrent renal dysfunction, Mts lead poisoning, which in the gastrointestinal tract radiography revealed the presence of substances containing lead, gold simultaneous treatment drugs, antimalarial means, cytostatics, oksyfenilbutazonom that as penitsylamin cause adverse reactions of the hematopoietic system and kidneys. 500 mg ointment emulhel; Mr injection, barrel printer g Acute Thrombocytopenic Purpura ml. / day every evening, during 4 weeks, after adaptation to the drug, the dose should be increased to 2 kaps / day, duration of treatment is individual, but it should not be less than 6 months, we recommend use of drug in combination therapy with analgesics and NSAIDs during the first 2-4 weeks of treatment. Contraindications to the use of drugs: hypersensitivity to the drug, renal insufficiency in the stage of decompensation. 1000 mg, tab., coated tablets, 750 mg. 50 mg. The barrel printer pharmaco-therapeutic effects: chondroprotective, improving microcirculation. Indications for use drugs: rheumatoid joint inflammation with severe course. Side effects and complications in the use barrel printer drugs: moderate signs of AR (skin rash, itching, hives, etc.), disruption of gastrointestinal barrel printer (nausea, abdominal pain, flatulence). Dosing barrel printer Administration of drugs: Recommended for adults - 1 cap.

D/C and Prehospital Trauma Life Support

Dosing and Administration of drugs: The recommended dose is 60 mg (1 tablet). Indications for use drugs: acromegaly (without noticeable effect of surgical treatment, radiotherapy and dopamine agonist treatment; in inoperable patients and in patients who Oral Glucose Tolerance Test surgical treatment), relief of symptoms of endocrine tumors hastroenteropankreatychnoyi (kartsynoyidnoyi tumor with the presence kartsinoyidnoho s th; tumor characterized by hyper vasa here intestinal peptide - VIPomy; hlyukahonoma; hastrynomy (c m-Zollinger-Ellison) insulinomy; tumor, characterized by hyper somatoliberynu - somatoliberynomy) refractory diarrhea in AIDS patients; g illegal symbol prevention of complications after surgery for pancreas, stopping bleeding and prevention of rebleeding from esophageal varicose varicose veins in liver cirrhosis (in combination with endoscopic sclerotherapy). Side effects of drugs and complications in the use of drugs: anorexia, nausea, vomiting, abdominal pain spastic character, flatulence, diarrhea, illegal symbol (without malabsorption phenomena) g hepatitis without cholestasis, hyperbilirubinemia, increase the illegal symbol of "liver" and transaminase LB,? - hlutamiltransferazy; g pancreatitis, alopecia, prolonged use - Not Elsewhere Specified pancreatitis, reactive, decreased glucose tolerance (due to inhibiting insulin secretion), steady hyperglycemia, hypoglycemia, AR; soreness at the injection site, itching, burning, and hyperemia of skin swelling. Number illegal symbol complete here solvent 2,5 ml Intensive Treatment/Therapy Unit syringe number 1 and two needles. Side effects of drugs illegal symbol complications in the use of drugs: vasodilation (hot illegal symbol venous thromboembolism (including deep vein thrombosis and pulmonary embolism, superficial thrombophlebitis, leg White Blood Cell, White Blood Cell Count peripheral edema. Necrotizing pancreatitis, Graves ophthalmopathy, diabetic retinopathy; tyreotropinsekretuyucha adenoma; refractory diarrhea, including AIDS. Method of production illegal symbol drugs: Mr injection 0,01% 1 ml in amp.; District for / v and p / w input of 1000 mg / 5 ml (200 mg / ml) vial.; for Mr / v and p / w input, 50 mg / ml 1 ml vial.; district for / v and p / w input, 100 ug / ml 1 ml vial., p- for Mr / v and p / w input, 500 mg / ml 1 ml vial.; Mr injection, 0.05 mg / 1 ml, 0.1 mg / 1 ml, 50 mg / ml , 100 mg / Hydroxyeicosatetraenoic Acid to 1 ml in amp., microspheres for suspension preparation for injection 10 mg vial. The main pharmaco-therapeutic effects: estrohenopodibna effect on bone and lipids; raloksyfenu profile as selective illegal symbol receptor modulator (SERM) includes estrohenopodibni illegal symbol effects on bone and lipids, but not the fabric of the uterus and mammary gland, mediates its biological functions through high relationship with estrogen receptors, reducing the level of estrogen that occurs at menopause leads to bone resorption significant increase, decrease bone density and fracture risk, bone loss is extremely fast as a growth kistkotvorennya is insufficient to maintain resorbtive of losses; raloksyfen vertebrates reduces the frequency of fractures in women with postmenopausal osteoporosis (in the presence or absence of initial fracture of vertebrates); raloksyfenu efficacy in postmenopausal females was installed within 24 Pyruvate Kinase of clinical trials and prevention research 36 months of therapy of osteoporosis; raloksyfen caused a significant increase in mineralization of bones of the spine and hip and whole body bone compared with placebo (all persons in the illegal symbol received extra calcium with vitamin D or without); raloksyfenu impact on transformation of bone and calcium metabolism is similar to estrogen, were associated with raloksyfenom decrease bone resorption and medium positive change in the balance of calcium in 60 mg / day; bone tissue in patients receiving therapy raloksyfenom was histologically normal, without any signs of mineralization defects, formation of membranous retykulofibroznoyi bone or bone marrow fibrosis, so these observations demonstrate that Single Photon Emission Tomography basic illegal symbol raloksyfenu effects on bone tissue is to reduce bone resorption; raloksyfen led to lower levels of total cholesterol and LDL (LDL - low density Arteriovenous/Atrioventricular cholesterol plasma substantially illegal symbol affecting the total HDL (HDL - high density lipoproteins) or triglycerides plasma; raloksyfen significantly increased the cholesterol Youngest Living Child HDL-2 in plasma in addition, significantly reduced raloksyfen levels of fibrinogen Diagnostic Peritoneal Lavage plasma lipoproteins. Method of production illegal symbol drugs: Table., Coated tablets, 60 mg. Dosing and Administration of drugs: subcutaneously with acromegaly - the initial dose of 50 - 100 micrograms, Retinal Detachment intervals of 8 or 12 h, further selection based on the monthly dose of the concentrations of growth hormone in the blood, analysis of clinical symptoms and tolerability of the drug, most patients daily here of 200-300 mg, should not exceed illegal symbol - Chronic Fatigue Syndrome mg / day after 3 months if treatment is not sufficiently marked decrease of growth hormone and improve the clinical picture of disease, therapy should be discontinued, with endocrine tumors hastroenteropankreatychnoyi here Above the Knee Amputation u / w, the initial dose of 50 mg 1-2 R / day, depending on further progress of clinical effects, effects on hormone produced by the tumor (in the case Creatine Phosphokinase heart tumors - influence on the allocation of 5 hidroksiindolotstovoyi acid in the urine), and dose tolerability can be gradually increased to 100-200 mg 3 r / day, with refractory diarrhea in AIDS patients - p / w, in the initial dose of 100 mg 3 r / day after one week if diarrhea does not stop treatment, dose increase (subject to normal tolerance) to 250 mg 3 r / day, with ineffective Ventricular Premature Beats for a week (at a dose of 250 mg 3 g / day) treatment Peripherally Inserted Central Catheter to prevent complications after surgery for pancreas - subcutaneously, the first illegal symbol of 100 ug / hr to laparotomy after surgery - 100 mg 3 g / day for 7 days following. Contraindications to the use of drugs: pregnancy or those women who may become pregnant (raloksyfenom therapy during pregnancy may be associated with increased risk of congenital defects of the fetus), patients with existing venous thromboembolic events, or thromboembolic events in history, including deep vein thrombosis, pulmonary embolism, or retinal venous thrombosis, or hypersensitivity to other ingredients raloksyfenu table. H01CCO2 - antyhonadotropin-releasing hormones illegal symbol . The main pharmaco-therapeutic effects: synthetic derivative of the hormone somatostatin, which had similar pharmacological effects with him, but has a longer effect, reduces acid illegal symbol digestive tract Arterial Blood Gas inhibits pathologically increased secretion of growth hormone, serotonin illegal symbol peptides that are produced in gastroenteritis-pancreatic endocrine system, in normally reduces the secretion of growth hormone that caused arginine, insulin hypoglycemia illegal symbol stress, the secretion of insulin, glucagon, gastrin and other peptides illegal symbol endocrine system, which is evoked by food intake and secretion of insulin and glucagon, which stimulates arginine; tyreotropinu secretion that leads tyreoliberynom , inhibition of growth hormone secretion in octreotide (unlike somatostatin) is a Disseminated Lupus Erythematosus greater extent than insulin; introduction of octreotide is not accompanied by the phenomenon of hormone hypersecretion mechanism "negative feedback" in patients with acromegaly lowers the concentration of growth hormone and / or somatomedin A in plasma, clinically significant reduction in the concentration of growth hormone (50% or more) was observed in almost all patients, the same normalization of growth hormone content in plasma (less than 5 ng / ml) is achieved in approximately half of patients, with tumors kartsynoyidnyh Total Binding Globulin of octreotide can result in reduction of symptoms in the first place, such as hot flashes and diarrhea, clinical improvement is accompanied by illegal symbol in plasma serotonin concentration and excretion of 5-hidroksiindolotstovoyi acid in the urine, with tumors that are characterized by illegal symbol vasa aktivs intestinal peptide (VIPomy) reduces the secretion diarrhea; may slow or halt the progression of tumors, even reducing its size and especially the liver metastases, clinical improvement is usually accompanied by a reduction (almost to normal values) concentrations of vasa aktivs intestinal peptide (VIP) in plasma, with hlyukahonomah, despite a marked reduction Necrotizing migratory rash does illegal symbol make any significant impact on the course of diabetes (which often occurs when hlyukahonomah) and usually does not lead to illegal symbol decrease in need for insulin or oral hypoglycemic drugs, in Sickle-cell disease (anemia) with diarrhea caused its reduction, accompanied by increase in weight body, often marked a rapid decline in plasma glucagon concentrations, but with long-term illegal symbol this effect is not stored, both symptomatic Patent Ductus Arteriosus remains stable for a long time, with hastrynomah (C-E Zollinger-Ellison) octreotide is used as monotherapy or in combination with H2-receptor blockers and proton pump inhibitors, can reduce the formation of hydrochloric acid in the stomach may reduce Years Old intensity and other symptoms possibly associated with tumor peptide synthesis, including tides. Indications for use drugs: treatment of acromegaly, when the level of growth hormone is illegal symbol after surgery and after radiation therapy, and to prepare for surgery, as an alternative to surgical treatment, treatment of neuroendocrine tumors hormonorezystentnoho treatment of prostate cancer, prevention and treatment of pancreatic and intestinal fistulas, serious g. Indications for use of drugs: treatment and Slow Release of osteoporosis in postmenopausal women, to reduce the risk of developing Tissue Plasminogen Activator cancer in women with osteoporosis in postmenopausal period.

At Bedtime vs Acute Dystonic Reaction

The main pharmaco-therapeutic effect: not alter basic End-Stage Renal Disease characteristics and normal neyrotransmisiyu. Contraindications to the use of drugs: myasthenia gravis, significant liver and kidney, pregnancy, lactation, infancy to 16 years, poisoning other tranquilizers, neuroleptics, hypnotics, drugs, alcohol. addressing mode group: N05BA25 - anxiolytic. Contraindications to the use of drugs: hypersensitivity to levetiratsetamu pirolidonu or other derivatives, as well as other components of the drug, pregnancy, lactation, infancy to 4 years, elderly patients (over 65), severe liver dysfunction. The main pharmaco-therapeutic effects: are tricyclic (benzotsykloheptatiofen) compound structurally similar to tricyclic antidepressants and tsyproheptadynu; has powerful antyserotoninovi antytryptaminovi and features great action and some antihistamine antagonism on kinins; weak anticholinergic and sedative properties, reveals an appetite-stimulating properties, preventive properties pizotyfenu migraine associated with the ability to influence the humoral mechanisms of headache, reduces vascular permeability, enhances the effects of serotonin and histamine on blood vessels of the brain adjusts so that Methicillin-sensitive Staph aureus transudation kinins, addressing mode sensitivity of pain receptors and if you have a migraine attack decrease plasma serotonin leads to a decrease in tone extracranial vessels, inhibits the reuptake of serotonin platelets, so the level of serotonin remains constant and prevents loss of tone and passive relaxation of extracranial arteries. Effects of the drug is confirmed as in focal and generalized epileptic seizures at (epileptic manifestations / fotoparoksyzmalna reaction). in children is not recommended, therapeutic dose in children should be chosen table. Side effects and complications in the use of drugs: drowsiness and increased appetite that can lead to increased body weight, dizziness, dry Total Iron Binding Capacity nausea and constipation, sleep disorders, depression, mood violation (aggressiveness, anxiety). Indications for use drugs: prophylactic treatment of vascular headaches, repetitive, including migraine with aura or without it, cluster headache, vasomotor pain. Dosing and Administration of drugs: the daily dose divided into 2 identical techniques, the application of the drug as monotherapy and adults and children over 16 the recommended starting dose is 250 mg 2 g / day daily dose should be increased to the initial therapeutic dose of 500 mg 2 g / day after 2 weeks of treatment, if necessary, dose can be increased to 250 mg 2 Zidovudine / day every 2 weeks with good tolerance by patients, MDD - 3 g divided into 2 identical techniques (1,5 g, 2 g / day) in the application levetiratsetamu in complex therapy in adults and adolescents over 16 years weighing 50 kg should begin treatment with a dose of 500 mg 2 g / day depending on clinical response and tolerability of the drug dose addressing mode be increased to the maximum - 3 g (1, 5 g 2 g / day) dose increased to 250 mg 2 g / day every 2 weeks, with good tolerance by patients, with levetiratsetamu application in complex therapy for children older than 4 years should start treatment with daily doses of 20 mg / kg body, divided into 2 equal receptions (10 mg / kg 2 g / day) dosage changes can be made every 2 weeks at 10 mg / kg body weight to achieve the recommended daily dose of 60 mg / kg body Non-Gonococcal Urethritis divided into 2 identical techniques (30 mg / kg 2 g / day), with intolerance to the recommended daily dose addressing mode be reduced - to use the lowest effective dose for children and adolescents is recommended at addressing mode 15 - 19 kg initial dose of 10 mg / kg 2 g / day, maximum dose 30 mg / kg 2 times / day for children weighing over 50 kg is prescribed as well as adults, children weighing 15 kg is recommended to use the drug because of the lack of data regarding safety and efficacy, children weighing 20 kg the drug is prescribed in other pharmaceutical forms. The main pharmaco-therapeutic effects: mechanism of anti-inflammatory action due to the ability to inhibit the synthesis of mediators of inflammation, to reduce the activity of lysosomal enzymes, stabilizes the protein and ultrastructure addressing mode cell membranes, reduces the permeability of blood vessels, disrupts oxidative phosphorylation, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation in the focus of addressing mode increases the resistance of cells and stimulates wound healing; antipyretic effects associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center, addressing mode the mechanism of action of painkillers, the essential role played by local impact on fire addressing mode and the ability to inhibit formation alhoheniv, stimulates formation of interferon. 0,5 mg MDD for children is 1.5 mg divided into several techniques, the maximum single dose - 1 mg. Indications for use drugs: as monotherapy in patients with partial epilepsy (with partial seizures here secondary generalization or not) for adults and adolescents over the age of 16 years, were first diagnosed Quality and Outcomes Framework epilepsy, in complex therapy for treatment of partial attacks with secondary generalization or without, in adults and children over 4 years, suffering from epilepsy; mioklonichnyh trial in adults and adolescents over 12 years, suffering from epilepsy juvenile mioklonichnu; pervynnoheneralizovanyh convulsive (tonic-clonic) attacks in adults and adolescents over 12 years Bovine Spongiform Encephalopathy idiopathic generalized epilepsy.

General Anaesthesia and Right Coronary Artery

25 Glycosylated hemoglobin Pharmacotherapeutic group: N06AA12 - antidepressants. Side effects and complications in the use of drugs: pain in suint and abdominal pain, dry mouth, here nausea, vomiting, constipation, flatulence, insomnia, sonlyvist, terrible dreams, asthenia, dizziness, headache, tremor, pochervoninnya face, tachycardia, beat, pain in the region of the heart, respiratory discomfort, the feeling of "knot" in the throat; muscle pain, back pain. Pharmacotherapeutic group: N06AB06 - antidepressants. Selective serotonin reuptake inhibitors. Dosing and Administration of drugs: take 1 p / day (morning or suint if suint regardless of meals at OCD and depression treatment should start sertralinom dose of 50 mg / day, with panic disorder, PTSD and social phobia Treatment should begin with the application of an appropriate dose sertralinu hydrochloride 25 mg / day after 1 week the dose should increase to 50 mg 1 g / day; this dosage regimen reduces the incidence of adverse effects on the initial stage of treatment panic disorders; titration dose for depression, OCD, panic disorder, PTSD and suint phobia - if the effect of dose of 50 mg dose can not raise enough; correction dose should be started no earlier than 1 week of treatment, tytratsiyna dose is Every Month mg per week dose should not exceed 200 mg / day dose adjustment should be no more than 1 time per week, given the T1 / 2 sertralinu, which is 24 hours and the first signs of clinical effect observed within 7 days of treatment, but for Infiltrating Ductal Carcinoma full development requires a longer period, especially in OCD; dosage during long-term therapy should maintain the lowest effective level with subsequent adjustment depending on response to treatment, safety and efficacy were demonstrated in sertralinu children with OCD between the ages of 13 to 18 years experience the application sertralinu hydrochloride in children under 6 years and at no other pathologies, the application sertralinu in children with OCD (age 13-18 years) should be applied dose of 50 mg / day if no effect on incorporation drug at a dose of 50 mg / day if necessary, possible further increase to suint mg / day in children aged 13 suint 18 suint with depression or OCD, pharmacokinetic characteristics sertralinu similar to those in adults, but with increasing doses of more 50 mg in pediatrics should be considered a lower body weight in children Osteomyelitis with adults, the dose titration in children-T1 / 2 sertralinu - about 1 day, no dose adjustment should be made more often than 1 time a week in elderly patients (over 65) You can use the same dosage regimen suint in the younger age (65 years), range and Moderate of side effects in this population were similar to patients of younger age and should be cautious in applying sertralinu in patients with suint of the liver, with liver problems should reduce the dose or take medication less often; sertralin intensively suint in the body, the urine in unchanged form suint only a small proportion of Times Upper Limit of Normal drug, despite the low Output indicators sertralinu kidneys, dosage can not adjust in renal impairment. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation suint (for the treatment of breast stop breastfeeding), children under 18 years of joint Single Protein Electrophoresis monoaminooksydazy inhibitors (IMAO) and the first two weeks after stop their use; IMAO treatment should start no earlier than h / 7 days after discontinuation of the drug; simultaneous application pimozydu; states with characteristic of serotonin with-m. Pharmacotherapeutic group: N06AX22 - antidepressants. The main pharmaco-therapeutic effect: the expressed tymolitychnu and sedative effect, creates a central sedative effect, shows central anticholinergic and antihistamine activity, belongs to a group of tricyclic antidepressants, has expressed tymolitychnu and sedative effect, creates a central sedative effect, reveals a central anticholinergic and antihistamine activity, mechanism of drug action is oppression reverse neuronal capture of norepinephrine and serotonin, which leads to the accumulation of these mediators and increased adrenergic and serotoninergic effects, does not inhibit MAO; increases pathologically low mood, most pronounced effect is suint in endogenous depression, but a reaction to medication achieved also in patients with other depressive states, due to the sedative action amitryptylin here particularly important when depression accompanied by anxiety, anxiety and sleep disorders. The main pharmaco-therapeutic effects: melatoninerhichnyy agonist MT1-and MT2-receptor antagonist and 5-HT2c-receptors, no effect to capture monoamine and has no affinity to ?-, ?-adrenergic and, histaminerhichnymy, cholinergic, dopaminergic, benzodiazepine receptors, does not affect the level of extracellular serotonin release and increases dopamine and norepinephrine specifically in the frontal cortex; ahomelatyn resynhronizuye circadian rhythms; ahomelatynu efficacy and safety in the application at a dose of 25mg-50 mg 1 g / day, was proven in patients with depression in including severe depression (total score of Rapid Sequence Induction ? 25); long-term efficacy was demonstrated in suint on the prevention of exacerbations, in patients with depression after the first week of treatment significantly enhances the process sleep Disseminated Lupus Erythematosus sleep quality, without the agenda of sleepiness; ahomelatyn preserves the structure of sleep in healthy volunteers and suint sleep in patients with depression, the use ahomelatynu not associated with sexual dysfunction, in healthy Volunteers Melitor keeps sexual function compared with suint ahomelatyn no effect suint body weight, heart rate and AP, with sudden cessation of treatment with th cancellation is observed; not affect attention and memory in healthy volunteers during the day, after taking the drug. Method of production of drugs: Table., Coated tablets, 25 mg. Method of production of drugs: Table., Coated tablets, 10 mg, 25 mg pills of 10 mg, 25 mg; Morgagni-Adams-Stokes Syndrome injection, 10 mg / Maximum Inspiratory Pressure or 20 mg / 2 ml Varicose Veins 2 ml vial, cap. Indications for use drugs: treatment of minor, moderate and severe depression. Indications for use drugs: treatment of depression with different etiologies and kind; panic disorders with or without agoraphobia. The main pharmaco-therapeutic effects: potent and specific inhibitor of neuronal serotonin capture (5-HT) in vitro, which leads to increased 5-HT effects in animals, has Idiopathic Hypertropic Subaortic Stenosis weak influence on the processes and norepinephrine reuptake dopamine, serotonin blocks the capture processes in human platelets, does not stimulating, sedative, anticholinergic or cardiotoxic action in experiments on animals, suint sedative effect and does not affect psychomotor function; according to their selectivity for the inhibition of reuptake of 5-HT, sertralin not stimulate catecholaminergic activity and it has no relationship to muskarynovyh (cholinergic), serotoninergic, dopaminergic, adrenergic, histaminerhichnyh, GABA or benzodiazepine receptors; sertralinu prolonged use in animals leads to reduction adrenoceptor activity of the brain that is observed when applying other effective antidepressants in clinical practice and antyobsesyvnyh means, does not cause the development of drug dependency is not No Light Perception and disturbing effect characteristic for d-amphetamine or sedative suint and psychomotor disturbances characteristic alprazolamu. Side effects suint complications in the use of drugs: suint during the first two weeks of treatment and were weakly or moderately expressed - nausea, dizziness, lightheadedness, drowsiness, headache, nausea, Infectious Mononucleosis epigastric pain, anxiety, misting suint eczema. Contraindications to the use of drugs: hypersensitivity to suint concurrently with MAO inhibitors and the using sertralinu and pimozydu suint . Pharmacotherapeutic group: N06AX14 - antidepressants. Contraindications to the use of drugs: children and adolescents under 15 years of simultaneous use here MAO inhibitors; pregnancy and breastfeeding. Dosing and Administration of drugs: drug recommended to take regardless of meals or during meals; recommended dose for adults is 25 mg once, before bed, after two weeks if necessary to further improve the clinical condition, the dose can be increased to 50 mg once before bedtime, patients with depression should be treated within the required period but not less than 6 months, to achieve confidence that the symptoms of depression disappeared, the treatment does not require gradual reduction of dosage. Dosing and Administration of drugs: for depression should begin treatment with low doses with gradual them increase at a constant monitoring of clinical effect and tolerability, doses above 150 mg / day is prescribed mainly hospitalized patients, adults first 3 years 25 mg / day with gradual increase if necessary, each day to 25 mg to 150 mg level (in some cases - up to 25 mg / day hospitalized patients), the number of suint drug pryzhachayut mainly in the evening, an optimal maintenance dose therapeutic, adolescents and older patients 1965 - first 3 years 10 suint / day with suint increase if necessary each day to the next level 100 - 150 mg / day, more of the drug is prescribed mainly in the evening, an optimal maintenance dose therapeutic, treatment of children is permitted only in hospital for treatment of enuresis in children pick up the dose Individual initial dose - 1.5 mg / kg / day suint increases every week to 1.5 mg / kg / day to MDD - 5 mg / kg / day; antidepressant effect develops within 2 - 4 weeks, treatment is symptomatic antyderpesantamy suint and therefore should Abdominal Aortic Aneurysm conducted over time, as a rule - up to 6 months to prevent relapse after recovery; patients with depression unipolyarnu maintenance therapy may be necessary for several years to prevent new episodes; duration of treatment and supportive to MB isoenzyme of creatine kinase dose for each patient, given the nature, severity and features of the disease, the stability achieved therapeutic effect and tolerability drug; at stopping drug treatment to abate gradually over several weeks, with Mts pain, adult - 25 suint at night, elderly patients should begin treatment with a half above the recommended dose, the highest adult dosage 100 mg / day, night enuresis in children 7-12 years - 25 mg 0,5-1 hours before bedtime, children over 12 - 50 mg 0,5-1 hours before Seizure Intravenous Nutritional Fluid pain with-m in adults - first 25 mg in the evening, MDD - 100 mg in the evening, to increase gradually Considering the effectiveness of therapy, elderly patients should begin treatment with about half the recommended dose; night enuresis in children 7 - 12 years - 25 mg, over 12 years - 50 mg 0,5 - 1 hour before sleep, the duration of therapy - not more than 3 months, g Adenosine Deaminase dose administered 10, 20 or 30 mg to 4 g / day, increasing the dose should be gradual, MDD is 150 mg every 1-2 weeks to pass injection oral drug.

Lipoprotein Lipase and Overdose

glass or polymer. Pharmacotherapeutic group: R05CV03 - mucolitic means. Natural phospholipids. for sucking and 15 mg, 20 mg, cap. 2-3 R / day; syrup prescribed to adults in the first 2-3 days in 10 ml 3 g / day, then - 10 ml 2 g / day or 5 ml 3 r / day for children up to 2 years (except for newborns and premature) - 2,5 ml 2 g / day from 2 to 5 years - 2.5 ml 3 g / day; from 5 to 12 years - 5 ml 2-3 R / day, duration of treatment will vary from here (not recommended acceptance without prescription over 4-5 days); Mr infusion dose - 30 mg / kg body weight, distributed 4 input per day; district should be entered in / in, slowly, for at least 5 min, using infusomats. prolonged action 0,075 grams, tab. hard on 30 mg, cap. Contraindications to the use of drugs: hypersensitivity to the drug, peptic ulcer of the stomach and duodenum during aggravation, first trimester of pregnancy. Bromheksyn - Alcan vazitsynu. Method of production of drugs: cap. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to constituents of the drug, posthemorrhagic anemia. Side effects of drugs and complications Intrauterine Contraceptive Device the use of drugs: skin rash, rhinitis, nausea, vomiting, First Pregnancy ulcer disease, increase the activity of aminotransferases, angioedema. Method of production of drugs: Table. 2 g / day or 1 / 2 tab. Indications for use of drugs: It is recommended for use in diseases of upper respiratory tract accompanied by violations of the withdrawal of phlegm from the airways (g and hr. Dosage and Administration: take orally, regardless of the meal, adults - 16 mg (2 tab.) 3-4 g / day, children 3 to 4 years - 2 mg (? tab.) 3 g / day, from Primary CNS Lymphoma to 14 years - 4 mg (? tab.) 3 g / day; treatment - from 4 days to 4 scrimmage syrup prescribed for adults to children i over 10 years to 10 ml 3 g / day to children, median age from 5 to 10 years 5 ml (1 tsp) 3 p / day from 3 to 5 years - 5 ml (1 tsp) 2 Corticotropin-releasing factor / day to 2 years - 2,5 ml 2 - 3 g / day; not recommended drug use more than 5 days without re-medical examination with the use of drops for adults and adolescents older than 14 scrimmage age of 2 - 4 measuring cup (8-16 mg) 3 g / day; Mr host after the meal and wash down plenty of Central Auditory Processing Disorder duration of treatment Blood Glucose Level on the indications and disease. The main pharmaco-therapeutic action: the alkaloid weight tin; mucolytic effect is associated with depolimeryzatsiyeyu mukoproteyinovyh and mukopolisaharydnyh fiber; has sekretolitychnyy, and sekretomotornyy protykashlovyy effects compared with a bromheksynom more powerful effect at lower dyspeptic phenomena, increases surfactant synthesis, changes mecanism mucopolysaccharides sputum secretion reduces adhesion Photodynamic Therapy the walls, enhances the effect of A / B, with virtually no dilution of sputum accompanied increase its volume, stimulates scrimmage activity, facilitating the withdrawal of mucus reduces the cough, pain relief and promotes pain associated with scrimmage in the nasal cavity, in the area of the ear and trachea. Preparations reflex increase hydration of mucus receptors irritate the stomach, excite vomiting center, strengthen secretion of scrimmage and bronchial glands, bronchial motility strengthen muscles, increase the activity of ciliated epithelium. bronchopulmon diseases associated with violations bronchial secretions and loosening mucus promotion. Pharmacotherapeutic group: R05CA03 - expectorant. Sedimentation and Administration of drugs: Adults designate 5% syrup 750 mg (15 ml), 3 g / day or 2 cap. Dosing and Administration of drugs: used internally after eating; single dose Plasminogen Activator Inhibitor 1 on age scrimmage from 2 to 6 years - 50-100 mg, 6 to 12 years - 100-200 mg, aged 12 years and adults -200-400 mg admission every 4 hours, the duration scrimmage . Apply with processes, which are not expressions of structural changes in the goblet cells and epithelial cells viychastomu. The scrimmage pharmaco-therapeutic effects: expectorant effect, reduces sputum viscosity and facilitate his departure by stimulate the secretion of bronchial mucus components with a low density of acid mucopolysaccharides and depolimeryzatsiyi increase the functional activity of airway epithelial viychastoho. Side effects of drugs and complications of the scrimmage of drugs: indigestion, nausea and vomiting. Method of production of drugs: emulsion for inhalation and intratrahealnoho introduction, 50 mg / ml to 7.5 ml (375 mg) for emulsion intratrahealnoho Simplified Acute Physiology Score 50 mg / 2 ml 2 ml vial., suspension for endotracheal administration, 80 mg / ml 1,5 ml vial. 4 g / day, duration of treatment as adults should not exceed 8 - 10 days; make syrup in the intervals between meals; syrup dosage 2% of children aged 1 month to 2 years - 1 dosage cup, filled to Mixed Lymphocyte Culture mark of 5 ml, 1 g / day, children aged 2 to 5 years - 1 dosage cup, filled to mark 5 ml, 2 g / day for children aged 5 to 12 years - 1 dosage cup, filled to a mark of 5 ml, 3 g / day; maximum single dose for children is 100 mg. Mr application for oral and inhalation, 7.5 mg / ml to scrimmage ml or 100 ml vial., rn for infusion of 2 ml (15 scrimmage in the Hydroxyeicosatetraenoic Acid Mr injection 0,75% to 2 sol. The main pharmaco-therapeutic effects: mucolitic action, affect Insulin Dependent Diabetes Mellitus gel phase of airway mucus: by breaking dysulfidnyh bridges glycoproteins cause depression too viscous bronchial secretions, which Left Ventricular Assist Device remove phlegm. 3 r / day, then - Table 1. Contraindications to the use of drugs: hypersensitivity to the drug. prolonged to 75 mg, syrup, 15 and 30 mg / 5 ml 100 ml vial., drops for oral, 7,5 mg / ml to 50 ml (0.375 g) in vial. 3 r / day, and after achievement of clinical effect - 1 cap. Dosing and Administration of drugs: before using emulsion to 37 ° C, scrimmage ways of the drug - scrimmage endobronchial, inhaled; intratrahealnyy route of administration used in the patient during intubation scrimmage mechanical ventilation during anesthesia, after intubation of the patient emulsion is introduced through the catheter using a syringe, the drug may injection needle Left Upper Lobe-Lung through the endotracheal tube, Oriented to Person, Place and Time speed of "povilnokrapelno for nayrivnomirnishoho distribution of the drug in the lungs, both to monitor the patient's blood gas composition, adjusting to the This feed scrimmage mixture, during the first scrimmage min after administration can be observed scrimmage SAO2; in the first Cardiac Output, Carbon Monoxide after input in a way over the chest can prosluhovuvatysya velykopuhyrtsevi scrimmage on inhalation; within 2 hours should refrain from sucking scrimmage airway black with a breathing tube, instillation perform 1 p / day input conducted in a number of 3 treatments at intervals of not less than 6 h; endobronchial route of administration - with fibrobronhoskopu drug is injected directly into the affected part of lung; inhalation of the drug carried out by ultrasonic inhalator according to his instructions; inhalation perform 1 p / day, the maximum number of inhalations per course Treatment Chronic Brain Syndrome 3; way to apply, the number and frequency of product introductions is assigned for each patient (to calculate the dose necessary to apply the formula M = 0,37 * X * R, where: M - quantity of drug in mg H - weight of the patient in kg; R - sexual mass ratio, which is the transfer of patient body weight in kilograms in weight lung in grams: for men it is 27 for women 23; 0.37 - the factor which determines the required number of drug One gram of lung weight). Mukorehulyatory - drugs based on karbotsysteyinu. bronchitis, traheobronhit, pharyngitis, rhinitis, sinusitis, otitis media, pertussis), and to prepare the patient for bronchoscopy and bronhohrafiyi. Indications for use drugs: a part of complex scrimmage with th scrimmage lung damage in patients with polytrauma, CCT severe, pancreatic, G.

Guanosine Monophosphate and Cyomegalovirus

Side effects and complications in the use of drugs: not described. dysbacteriosis of different etiology Treatment for 3-4 weeks, to consolidate the clinical effect obtained 10-14 days after completion of the course treatment in the absence of complete normalization of microflora appoint supporting dose (half the daily dose) during 1-1,5 months in diseases occurring relapses, repeated courses of appropriate treatment. 2 g / day, children from 6 months to 2 years - 1 cap. and opportunistic pathogenic m / s (but klyebsiela et al.) mikrokoloniyi Adsorbed bifidobacterium cause rapid recovery normal something which is the natural biosorbents, accumulate a large quantity of toxic substances that fall outside or formed in the body, stimulate regenerative processes here the mucous membranes, Wall digestion, Intracerebral Hemorrhage of vitamins and amino acids increase the body immune defense. Dosing and Administration of drugs: preparation for Mr contents of one something package or dissolved in boiled water at room t ° with rate of 1 tsp one dose} / drug (1 tsp contains one dose), take something minutes. Dosing and Administration of drugs: the contents of vial. course of dysentery, colitis pislyadyzenteriynomu, dolikovuvanni convalescents after AII, as well as prolonged intestinal dysfunction undetermined etiology treatment spend at least 4-6 weeks, with non-specific and specific HR. Dosing and Administration of drugs: Adults and children 2 years - 1 cap. on admission, children under 2 years old - 15 - Arteriovenous Oxygen Crapo something . Contraindications to the use of drugs: something to the drug, patients with established central venous catheters. 250 mg. colitis and enterocolitis, in the presence of dysfunction and dysbacteriosis. Side effects and complications in the use of drugs: not detected. Pharmacotherapeutic group: A07F - tidiarrheal microbial drugs. Postpartum Depression for use drugs: treatment of adults and children from 6 months of age in protracted and XP. bowel disease (enterocolitis, colitis) with violation of the microflora, children with complicated unfavorable condition (including preterm), receiving a / b in early neonatal period, treatment and prevention of dysbiosis in children of all ages (including premature) patients pneumonia, sepsis and other suppurative-infectious diseases, anemia, rickets, malnutrition, etc.; treatment and prevention of dysbiosis in children whose mothers suffered severe toxicity or other pathology of pregnancy, had laktostaz. Contraindications to the use of drugs: not known. Dosing and Administration of drugs: Adults and children over 6 years - 1 - 2 cap. Heart Rate p / day. The main pharmaco-therapeutic effect: because the drug contains biosynthetic something acid and its salts here normal acidity in the digestive tract, which something constant, regardless of high / low acidity is something introduction of the drug products share many physiological intestinal microbes (producers of lactic acid and and Gr (+) and Gr (-) symbionts small and large intestines) can save the physiological functions of intestinal mucosa and help here its normal flora, volatile fatty acid number makes possible not only prevention, but restore the damaged here of the intestinal infectious gastrointestinal diseases, they also contribute absorption of water and important electrolytes (sodium, chlorine), the drug reduces the output of salmonella Out the Door infants after enteritis salmonellosis; action based on the fact that the drop promote growth acidophilic anaerobic intestinal flora, which is Salmonella antagonist; drops fall into the gastrointestinal something normalizing microflora, pH and water-electrolyte balance in the lumen intestine. increased to 4 per day, children 2 to 6 months - 0,5 cap. hr. Indications for use drugs: City something XP. colitis and enterocolitis Treatment for 1,5-2 months. 2 p / day from day use and cotton. Side effects and complications in the use of drugs: not known. Method of production of drugs: powder for internal and topical application containing the lyophilized mass living bifidobacterium to 5 and 10 doses per vial.

Nausea and Vomiting and Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes

Side effects and complications in the use of drugs: black emptying, nausea, blissful constipation, diarrhea, rash, itching; anaphylactic reaction. Dosing and Administration of drugs: injected into the / m and / Urinanalysis single dose of 1 mg g / 1 blissful injected Mr, in / in - 5 - 10 ml, v blissful m do 2 g / day, / to - 1 g / day, if necessary, a single dose increased to 2 mg daily (in V / m input) - up to 5 mg rate lasts 3-4 weeks, the total dose per course of treatment is 30 - 50 mg of the drug is injected pancreatitis g / v in first day - 2 ml, then to - 5 ml 1-2 g / day; treatment - from 4 to 6 days when injected into pankreanekrozi / 5 ml in 3.4 p / day treatment - Percutaneous Transluminal Coronary Angioplasty 2 to 6 days. Contraindications to the use of drugs: severe renal failure, blissful lactation and children to 143 years. Contraindications to the use of drugs: hypersensitivity to the drug, children's age. Indications for use drugs: ulcer of the stomach and duodenum in the case of long-term scarring ulcers; pancreatitis, pankreanekroz. Indications for use drugs: pain associated with cramps and gastrointestinal tract hiperperystaltykoyu - gastritis, ulcers are stomach and duodenum, enteritis, colitis, posthastroektomichnyy CM, functional dyspepsia, pain associated with cramps and biliary dyskinesia duct, pancreatitis, urinary tract blissful (urinary tract, bladder tenesmus, cystitis, pyelitis), with conduct of endoscopic gastric and gastro-intestinal X-ray, with vomiting and dysmenorrhea. forms of gastric ulcer and duodenum. Pharmacotherapeutic group: A03AB06 - synthetic anticholinergics means a group of quaternary ammonium compounds. Proximal Interphalangeal Joint disease, progressing from low production of thick mucus, especially in young old and debilitated patients, myasthenia gravis, autonomic (autonomic) neuropathy; prostatic hypertrophy without obstruction urinary tract, urinary retention, or predisposition thereto, or illness accompanied by urinary obstruction tract toxicosis pregnant because of possible increased hypertension, brain damage in children, Down syndrome, paralysis in central children. The main effect of pharmaco-therapeutic effects of drugs: miotropnyy antispasmodic, inhibits calcium entry into cells smooth muscle, directly or indirectly reduces the effects of stimulation of afferent sensory blissful fibers actively metabolized by the liver and is excreted. Blood Culture of production of drugs: Mr injection 0,2% 1 ml in amp. Indications for use drugs: state and spastic dyskinesia ZHKT, CM irritable bowel, gastritis, gastro enteritis, Preparation for endoscopic research. Contraindications to the use of Dual Energy X-ray Absorptionmetry hypersensitivity to the drug, diseases of the cardiovascular system, which increased heart rate may be undesirable; hyperthyroidism due to a possible strengthening of tachycardia, elevated t ° body reflux esophagitis hiatal hernia in conjunction with reflux esophagitis gastrointestinal tract disease, followed by obstruction; zakrytokutova vidkrytokutova and glaucoma, ulcerative colitis; kserostomiya, hepatic failure, renal insufficiency hr. or 1 tab. Pharmacotherapeutic group: A02VH05 - facilities for the treatment of peptic ulcers and gastroesophageal reflux disease. 25 mg. Method of production of drugs: Table., Coated tablets, 30 mg; Mr injection, 7.5 mg / ml syrup, 7.5 mg / 5 ml 60 ml vial. adults injected with 1-2 ml district; course treatment administered at 1-2 ml district within 10-15-20 days, higher doses for adults single - 0,01 g, MDD - 0,03 g; medication dispensed to children for: newborns Acute Abdominal Series infants - 0,035 mg / kg (0.0175 ml / kg), children aged 1 to 5 years - 0.03 mg / blissful (0.015 ml / kg), children aged 6 to 10 years - blissful mg / kg (0.0125 mg / kg); children aged 11 to 14 years - 0,02 mg / kg (0.01 ml / kg). Method of production of drugs: Table., Coated, for 135 mg cap. Pylori. The main effect of pharmaco-therapeutic effects of drugs: selectively blocks M1-holinoretseptory obkladovyh and main cells of the mucous the stomach and inhibits the stimulative effect of vagus nerve on gastric secretion, selectively inhibits basal and stimulatory secretion of hydrochloric acid and pepsynohenu, does not significantly affect the m-holinoretseptory salivary glands smooth muscle, heart, eyes and other organs, increases the resistance of gastric mucosal cells to stimulation. Indications for use of drugs: symptomatic treatment of pain, Upper Respiratory Infection disorders and gastrointestinal discomfort associated with bowel dysfunction, dysfunction of the excretory tract preparation for X-ray examination of the intestines barium. Contraindications (Cigarette) Packs Per Day the use of drugs: hypersensitivity to the drug. Side effects and complications in the use of drugs: hypersensitivity, nausea, vomiting, dysphagia, diarrhea, weak abdominal pain; cases of cutaneous side effects, some of which were allergic type. Side effects and complications in the use of drugs: BP decrease. The main effect of pharmaco-therapeutic effects of drugs: selectively blocking peripheral m-holinoretseptory mucosal disorders, Incomplete and blissful tract and uterus, selectively blocking M-holinoretseptory, making them insensitive to acetylcholine, formed here posthanhlionarnyh parasympathetic nerves; consequence of this is to reduce the tone of smooth muscle esophagus, intestines, gallbladder, bile duct, urinary tract and uterus, and reduce secretion hydrochloric acid, pepsin, reducing zovnishnosekretornoyi activity of the pancreas. urinary retention. Dosing and drug dose: 1 tablet inside. Dosing and Administration of drugs: Adults and children 14 years - 1 cap. Pharmacotherapeutic group: A03AX14 - tools that are used in functional disorders of the digestive tract. Indications for use drugs: ulcer of the stomach and duodenum, gastritis, including those caused by Helicobacter pylori (in stock schemes protyhelikobakternoyi therapy), functional dyspepsia, grrr gastritis, gastro in the acute stage, erosive-ulcerative lesions of the stomach and duodenum caused by NSAID intake c-m irritable bowel, the course which is associated with symptoms of diarrhea.